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Abstract
Background:  Meta-analyses of N-acetylcysteine (NAC) for preventing contrast-induced
nephrotoxicity (CIN) have led to disparate conclusions. Here we examine and attempt to resolve
the heterogeneity evident among these trials.
Methods:  Two reviewers independently extracted and graded the data. Limiting studies to
randomized, controlled trials with adequate outcome data yielded 22 reports with 2746 patients.
Results: Significant heterogeneity was detected among these trials (I2 = 37%; p = 0.04). Meta-
regression analysis failed to identify significant sources of heterogeneity. A modified L'Abbé plot
that substituted groupwise changes in serum creatinine for nephrotoxicity rates, followed by
model-based, unsupervised clustering resolved trials into two distinct, significantly different (p <
0.0001) and homogeneous populations (I2 = 0 and p > 0.5, for both). Cluster 1 studies (n = 18; 2445
patients) showed no benefit (relative risk (RR) = 0.87; 95% confidence interval (CI) 0.68–1.12, p =
0.28), while cluster 2 studies (n = 4; 301 patients) indicated that NAC was highly beneficial (RR =
0.15; 95% CI 0.07–0.33, p < 0.0001). Benefit in cluster 2 was unexpectedly associated with NAC-
induced decreases in creatinine from baseline (p = 0.07). Cluster 2 studies were relatively early,
small and of lower quality compared with cluster 1 studies (p  = 0.01 for the three factors
combined). Dialysis use across all studies (five control, eight treatment; p = 0.42) did not suggest
that NAC is beneficial.
Conclusion: This meta-analysis does not support the efficacy of NAC to prevent CIN.
Background
Since its development, meta-analysis has become a pow-
erful tool for informing clinical practice. Performed cor-
rectly, meta-analysis is superior to a purely narrative
approach of summarizing medical research. As such,
robust conclusions may sometimes be reached from
serial, otherwise underpowered small studies [1,2]. None-
theless, there are substantial limitations and pitfalls in
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meta-analysis. Publication bias, reliance on subjective
summary results rather than individual patient data and
the mishandling of important heterogeneity can all lead
to erroneous conclusions [1-8]. This possibility is under-
scored by the occasional lack of concordance between
meta-analyses and subsequent large randomized, control-
led trials [3,9].
Over the past decade, the efficacy of N-acetylcysteine
(NAC) for preventing contrast-induced nephrotoxicity
(CIN) has been explored in more than 60 clinical studies
[10-71], 12 meta-analyses [72-83] and two comprehen-
sive analyses of published meta-analyses [84,85]. Of the
meta-analyses, some declared that NAC is beneficial [72-
78] while others determined that the data are inconclusive
[79-83]. Significant heterogeneity was detected in all of
the meta-analyses that specifically tested for it and meta-
regression and other approaches have failed to resolve or
pinpoint the cause of the heterogeneity. This much-stud-
ied example, where meta-analysis may have increased
rather than decreased clinical ambiguity, provides an
opportunity to better understand and dissect complex het-
erogeneity problems in meta-analysis.
We assembled a meta-analysis of NAC efficacy in prevent-
ing CIN. Like previous attempts, we encountered signifi-
cant heterogeneity that was not explained using a
comprehensive meta-regression approach. A modified
L'Abbé plot [86] followed by the application of a model-
based, unsupervised clustering algorithm [87] resolved
the trials into two significantly different populations.
Clinical practices aimed at preventing CIN are discussed
and recommendations are made regarding future trials of
NAC.
Methods
This meta-analysis was completed in accordance with the
Quality of Reporting of Meta-analyses (QUOROM) state-
ment [2].
Literature search
We searched MEDLINE (PubMed and Dialog), EMBASE,
International Pharmaceutical Abstracts, Derwent Drug
File, Adis R&D Insight, Adis Clinical Trials Insight, Biolog-
ical Abstracts and CINAHL (OVID), the Web of Science
and The Cochrane Library. Searches included: controlled
vocabulary for acetylcysteine, contrast media/adverse,
toxic and poisoning effects; free text for acetylcysteine and
contrast; and MeSH terms acetylcysteine and contrast
media. Retrieved records from the Cochrane CENTRAL
file were re-checked in Web of Science to identify subse-
quent publications. Search dates were from the inception
of the databases until September 30, 2004. Conference
proceedings from the American Society of Nephrology,
National Kidney Foundation, American Heart Associa-
tion, American College of Cardiology, Society of Interven-
tional Radiology, Radiologic Society of North America
and International Society of Nephrology were also
reviewed over the past five years. There were no restric-
tions on language or publication status. Over 450 cita-
tions and abstracts were screened by two authors to
assemble a preliminary set of possibly relevant reports.
New publications after September 30, 2004 were periodi-
cally monitored using the same search criteria up to March
1, 2007.
Selection criteria
Studies were limited to prospective, randomized, control-
led trials (PRCTs) investigating the efficacy of NAC in pre-
venting CIN. Trials with confounded, non-concurrent or
otherwise improperly constructed control groups were
prospectively excluded from further analysis. Outcome
data were solicited from the authors if not found in the
publication. Trials that still lacked outcome data necessary
for planned analyses were excluded.
Quality assessment, data retrieval and clinical endpoints
Two of the authors evaluated each trial using the Jadad
scoring device, under unmasked conditions [88]. Each
PRCT included in the analysis scored at least 1 on the five-
point scale, with higher scores indicating greater trial
quality. Data were extracted independently into a stand-
ardized form. Results were compared and disagreements
were resolved by discussion. The primary outcome meas-
ures were the development of CIN as defined in the stud-
ies [10-31] and change in creatinine (ΔCre). The
occurrence of acute kidney injury requiring dialysis was
recorded. When not reported in the publication, we con-
tacted the authors for post-contrast dialysis information.
Meta-analysis and heterogeneity testing
Treatment effects were quantified by relative risk (RR)
using a random-effects model (Comprehensive Meta-
Analysis, Biostat Inc, Englewood, NJ). Statistical heteroge-
neity was assessed by means of a Mantel-Haenszel derived
Cochran's Q statistic and associated I2 value. Cochran's Q
is used to test the null hypothesis that all treatment effects
are equivalent [89]. Calculated from the Q-statistic and
degrees of freedom, I2 represents the proportion of treat-
ment effect variation owing to trial heterogeneity, rather
than simple sampling error [4,89,90]. Statistical heteroge-
neity is present when this variation in results exceeds the
amount expected from chance alone. The quantitative
pooling of such studies may lead to erroneous conclu-
sions [4].
Publication bias and meta-regression analysis
Evidence of publication bias was formally tested using
multiple methods including those of Begg and Mazumdar
[6], Egger et al. [5] and Higgins and Thompson [4]. Stand-BMC Medicine 2007, 5:32 http://www.biomedcentral.com/1741-7015/5/32
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ard meta-regressions of the effect size expressed as log RR
were performed against trial factors including publication
date, size and Jadad score. Well-known patient-related
risk factors associated with increased rates of CIN were
also evaluated by meta-regression including mean age,
diabetes mellitus (%), gender (% female), mean contrast
volume and mean baseline creatinine concentration [91-
94]. Likewise, total NAC dose was examined for its rela-
tionship with outcome. A separate meta-regression exam-
ined the log odds of developing CIN in the treatment
versus the control groups. This was used to detect whether
NAC efficacy was affected by the rate of CIN in the control
population [95,96]. All meta-regressions were weighted
by the inverse variance of each study.
Jackknife-k sensitivity analysis, modified L'Abbé plot and 
unsupervised clustering: detection of trial subpopulations
A sensitivity analysis for heterogeneity was completed by
means of a jackknife-k [97] procedure in order to detect
studies that contributed most to heterogeneity. A pre-
specified p-value greater than 0.2 for Cochran's Q statistic
and an I2 of less than 10% indicated homogeneity. Every
possible one-, two- and three-study combination was
removed.
The method of L'Abbé et al. [86] was used to visualize het-
erogeneity in our set of trials. As originally described, the
L'Abbé plot graphs the control group outcome rate along
the x-axis and the treatment group outcome rate along the
y-axis for each trial. To correct for differences in the defini-
tion of CIN across studies, we modified the L'Abbé plot by
substituting ΔCre, a continuous variable, for the CIN rate.
Compared with a standard L'Abbé plot (data not shown),
the modified plot was similar, but was better at separating
studies that were low and high contributors to heteroge-
neity.
We then analyzed our modified L'Abbé plot using an
unsupervised, model-based clustering method that creates
a best-fit Gaussian model and finds the number of clusters
that maximize the Bayesian information criterion. All
members of the data set are then classified using iterative
expectation-maximization methods and group member-
ship likelihoods are calculated [87]. The study and patient
characteristics of each cluster were then compared using
Wilcoxon rank sum tests. The decomposed Breslow-Day
test was used to determine whether the identified clusters
had significantly different treatment effects.
Results
Trial flow
The literature search identified 45 clinical studies investi-
gating NAC to prevent CIN (Figure 1). Ten studies were
retrospective [32-41]. Three studies were prospective but
not randomized [42-44]. Five studies were removed
owing to a lack of placebo controls [45-49]. Three studies
were excluded because CIN was not clearly defined [50-
52]. One abstract was excluded because discrepant out-
come results reported in the abstract and a subsequent
meta-analysis could not be resolved [53]. One study was
removed owing to a confounded design, where treated
patients received more fluid compared with controls[54].
Additional information required for analysis was
requested from trial authors; when unsuccessful in the
case of one abstract [18], data were extracted from other
meta-analyses. We included the more complete, updated
data from manuscripts that were published after our cut-
off date [55-57] if these studies had been available in the
form of abstracts [19-21] before September, 2004.
Table 1 lists the characteristics of the 22 trials meeting our
prospective selection criteria [10-31]. Figure 2 shows a for-
est plot ordered by time of publication, with RR and con-
fidence intervals (CIs) of developing CIN if treated with
NAC. A summary statistic is not shown owing to the sig-
nificant heterogeneity (I2 = 37%; p = 0.04) that precluded
the pooling of these trials.
Publication bias and meta-regression analysis
Although non-significant (p ≤ 0.11, but p > 0.05 when
applying any one of the three methods used for analysis),
a visual inspection of a funnel plot suggested publication
bias with four studies [10,11,14,25] contributing most to
the apparent asymmetry (shown with open circles on the
left-hand side of Figure 3). An extensive meta-regression
analysis of patient and study characteristics found no
study-specific characteristic (publication date, size, qual-
ity as measured by Jadad score or total NAC dose) or 
Study selection flow diagram Figure 1
Study selection flow diagram.
Clinical trials
screened
(n = 45)
Prospective, randomized,
controlled trials included
in meta-analysis
(n = 22)
No placebo control (n = 5)
Retrospective (n = 10)
Prospective, not randomized (n = 3)
CIN not defined (n = 3) 
Discrepant outcome data (n = 1)
Confounded design (n = 1)
Trials Excluded
Prospective, randomized,
controlled trials
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Table 1: Study Patient Characteristics
Authors 
(reference)
Pub. 
Date
Average 
patient 
age 
(years)
Per cent 
Male
BSCr 
(mg/dl)
Diabetes 
(%)
Contrast 
volume 
(ml)
Jadad 
Score
End point 
(SCr rise)
Contrast 
procedure
NAC 
regimen
Hydration 
regimen
Tepel et al. 
[10]
07/
00
65 NA 2.5 32.5 75 1 0.5 mg/dl 
48 h
CT 600 mg 
tablet bid 
× 4
0.45% 1 ml/kg/h 
12 h before, 12 h 
after
Diaz-
Sandoval et 
al. [11]
02/
02
73 80% 1.6 38.9 184 2 0.5 mg/dl 
or 25% 48 
h
LHC 600 mg 
liquid in 
ginger ale 
bid × 4
0.45% 1 ml/kg/h 
2–12 h before, 
12 h after
Briguori et al. 
[12]
07/02 64 86% 1.5 37.8 197 1 25% 48 h LHC and/or 
PA and/or 
PCI
600 mg 
tablet bid 
× 4
0.45% 1 ml/kg/h 
12 h before, 12 
h after
Vallero et al. 
[13]
09/02 62 NA 1.0 23.0 205 1 0.5 mg/dl 
or 33% 48 
h
LHC and/or 
PCI
600 mg 
tablet bid 
× 4
0.45% 1 ml/kg/h 
1–2 h before, 24 
h after
Shyu et al. 
[14]
10/
02
70 68% 2.8 63.5 117 1 0.5 mg/dl 
48 h
LHC ± PCI 400 mg 
powder 
bid × 4
0.45% 1 ml/kg/h 
12 h before, 12 h 
after
Allaqaband et 
al. [15]
11/02 70 NA 2.1 48.3 122 3 0.5 mg/dl 
48 h
LHC ± PCI 
or PA + 
PCI
600 mg 
liquid in 
cola bid × 
4
0.45% 1 ml/kg/h 
12 h before, 12 
h after
Durham et 
al. [16]
12/02 71 66% 2.3 48.1 81 3 0.5 mg/dl 
48 h
LHC 1200 mg 
liquid in 
orange 
juice bid 
× 2
0.45% 1 ml/kg/h 
≤ 12 h before, ≤ 
12 h after
Kay et al. 
[17]
02/03 69 62% 1.3 37.5 125 5 25% 48 h LHC and/or 
PCI
600 mg 
tablet bid 
× 4
0.9% 1 ml/kg/h 
12 h before, 6 h 
after
Loutrianakis 
et al. [18]
03/03 67 NA 1.9 36.0 147 1 0.5 mg/dl 
120–168 h
LHC 600 mg 
bid × 4
0.45% 1 ml/kg/h
Azmus et al. 
[19]
07/03 67 59% 1.3 49.6 126 5 0.5 mg/dl 
or 25% 
24–48 h
LHC or PCI 600 mg 
powder 
in water 
bid × 5
0.9% 1 L pre, 1 
L post, or none
Gomes et al. 
[20]
10/03 65 59% 1.3 51.9 103 4 0.5 mg/dl 
48 h
LHC or PCI 600 mg 
bid × 4
0.9% 1 ml/kg/h 
12 h before, 12 
h after
Nguyen-Ho 
et al. [21]
11/03 70 NA 1.4 67.5 347 4 25% 48–72 
h
LHC or PCI 2000 mg 
liquid in 
juice bid 
× 2 or 3
0.45% 75 ml/h ≥ 
24 h from enroll
Efrati et al. 
[22]
12/03 67 90% 1.5 52.9 140 2 25% 24–96 
h
LHC 1000 mg 
liquid in 
cola bid × 
4
0.45% 1 ml/kg/h
El Mahmoud 
et al. [23]
12/03 67 81% 1.9 30.0 177 2 25% 24–48 
h
LHC 600 mg 
orally bid 
× 2
0.9% 1 ml/kg/h
Kefer et al. 
[24]
12/03 62 77% 1.1 12.5 199 1 0.5 mg/dl 
or 25% 24 
h
LHC and/or 
PCI
1200 mg 
in 0.9% 
saline IV 
over 60 
min, 12 h 
pre 0 h 
post
0.9% 1 ml/kg/h
MacNeill et 
al. [25]
12/
03
73 86% 1.9 46.5 110 4 25% 72 h LHC ± PCI 600 mg 
liquid in 
juice/soda 
bid ×5
0.45% 1 ml/kg/h 
12 h or 2 ml/kg/h 
4 h before, 75 
ml/h 12 h after
Oldemeyer 
et al. [26]
12/03 76 55% 1.6 44.9 131 2 0.5 mg/dl 
or 25% 48 
h
LHC 1500 mg 
liquid in 
soda bid 
× 4
500 ml D5 20 
ml/h 12 h 
before, 12 h 
after
Goldenberg 
et al. [27]
02/04 70 83% 2.0 43.9 116 5 0.5 mg/dl 
48 h
LHC ± PCI 600 mg 
liquid in 
soda tid 
× 6
0.45% 1 ml/kg/hBMC Medicine 2007, 5:32 http://www.biomedcentral.com/1741-7015/5/32
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Forest plot of twenty-two studies meeting inclusion criteria for meta-analysis Figure 2
Forest plot of twenty-two studies meeting inclusion criteria for meta-analysis. Studies are ordered by date of publi-
cation. Lines represent 95% CIs. Box sizes represent the weight (by inverse variance) of each trial. Note a trend over time 
towards no effect. No summary statistic is shown owing to excessive heterogeneity.
CIN* / Total Relative risk and 95% CI
Relative risk 
    (95% CI) NAC Control p-Value
Tepel et al., 2000 [10] 1 / 41 9 / 42 0.11 (0.02-0.86) 0.04
Diaz-Sandoval et al., 2002 [11] 2 / 25 13 / 29 0.18 (0.04-0.72) 0.02
Briguori et al., 2002 [12] 6 / 92 10 / 91 0.59 (0.23-1.57) 0.29
Vallero et al., 2002 [13] 4 / 47 4 / 53 1.13 (0.30-4.26) 0.86
Shyu et al., 2002 [14] 2 / 60 15 / 61 0.14 (0.03-0.57) 0.01
Allaqaband et al., 2002 [15] 8 / 45 6 / 40 1.19 (0.45-3.12) 0.73
Durham et al., 2002 [16] 10 / 38 9 / 41 1.20 (0.55-2.63) 0.65
Kay et al., 2003 [17] 4 / 102 12 / 98 0.32 (0.11-0.96) 0.04
Loutrianakis et al., 2003 [18] 6 / 24 3 / 23 1.92 (0.54-6.77) 0.31
Azmus et al., 2003 [19] 14 / 196 17 / 201 0.84 (0.43-1.67) 0.63
Gomes et al., 2003 [20] 8 / 77 8 / 79 1.03 (0.41-2.60) 0.96
Nguyen-Ho et al., 2003 [21] 8 / 83 16 / 72 0.43 (0.20-0.95) 0.04
Efrati et al., 2003 [22] 0 / 24 2 / 25 0.21 (0.01-4.12) 0.30
El Mahmoud et al., 2003 [23] 3 / 60 2 / 60 1.50 (0.26-8.66) 0.65
Kefer et al., 2003 [24] 2 / 53 3 / 51 0.64 (0.11-3.68) 0.62
MacNeill et al., 2003 [25] 1 / 21 7 / 22 0.15 (0.02-1.11) 0.06
Oldemeyer et al., 2003 [26] 4 / 49 3 / 47 1.28 (0.30-5.41) 0.74
Goldenberg et al., 2004 [27] 4 / 41 3 / 39 1.27 (0.30-5.31) 0.74
Agrawal et al., 2004 [28] 2 / 11 2 / 14 1.27 (0.21-7.65) 0.79
Fung et al., 2004 [29] 8 / 46 6 / 45 1.30 (0.49-3.46) 0.59
Ochoa et al., 2004 [30] 3 / 36 11 / 44 0.33 (0.10-1.10) 0.07
Webb et al., 2004 [31] 14 / 194 12 / 204 1.23 (0.58-2.59) 0.59
0.01 0.1 1 10 100
Favors NAC Favors Control
Author, Year (Reference)
* CIN; Contrast-Induced Nephrotoxicity
NAC; N-acetylcysteine
Agrawal et al. 
[28]
04/04 63 68% 1.7 47.8 178 2 0.5 mg/dl 
or 25% 48 
h
LHC and/or 
PCI
800/600/
600 mg 
liquid in 
soda 12/2 
h pre/6 h 
post
0.45% 1 ml/kg 
12 h ± 250 ml 
bolus before, 12 
h after
Fung et al. 
[29]
05/04 68 70% 2.3 52.8 128 3 0.5 mg/dl 
or 25% 
decrease in 
GFR 48 h
LHC or PCI 
± PA
400 mg 
powder 
tid × 6
0.9% 100 ml/h 
12 h before, 12 
h after
Ochoa et al. 
[30]
06/04 71 43% 2.0 55.5 144 4 0.5 mg/dl 
or 25% 48 
h
LHC and/or 
PCI
1000 mg 
liquid in 
diet cola 
bid × 2
0.9% 150 ml/h, 
≥ 500 ml 12 h 
before, ≥ 1000 
24 h after
Webb et al. 
[31]
09/04 70 NA 1.7 34.9 120 5 0.5 mg/dl 
48–192 h
LHC or PCI 
± PA
500 mg in 
D5NS IV 
for 15 
min, 1 h 
pre
0.9% 200 ml 
before, 1.5 ml/
kg/h 6 h or 
discharge (<6 h) 
after
SCr, serum creatinine; BSCr, baseline serum creatinine; CT, computed tomography; LHC, left heart catheterization; PCI, percutaneous coronary 
intervention; PA, peripheral angiography; Jadad score, measure of study design quality (0 is the weakest, 5 is the strongest); NAC, N-acetylcysteine; NA, 
not applicable; bid, twice daily; tid, three times daily; IV, intravenous; h, hour; D5NS, 5% dextrose plus normal saline; 0.9%, normal saline; 0.45%, half-
normal saline.
Table 1: Study Patient Characteristics (Continued)BMC Medicine 2007, 5:32 http://www.biomedcentral.com/1741-7015/5/32
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patient-related characteristic (age, diabetes, gender, con-
trast volume, baseline creatinine or CIN event rate in the
control group) that significantly co-varied with NAC effi-
cacy (Table 2).
Sensitivity analysis
A jackknife-k sensitivity analysis [97] identified 10 studies
that decreased heterogeneity when individually removed
(right-hand side of Figure 4). Removal of any one of the
remaining 12 studies increased heterogeneity (left-hand
side of Figure 4). The four small studies [10,11,14,25] that
individually contributed the most to heterogeneity are
shown as open circles in Figure 4 (circle size is propor-
tional to inverse variance). Removal of any single study or
all possible two-study combinations failed to adequately
resolve heterogeneity. In contrast, the removal of multiple
three-study combinations (combinations
[11,14,25][10,11,14][11,14,21] and [11,14,17]) reached
our pre-defined target for homogeneity (after the removal
of any one of the three-study groups above, I2 ≤ 9.5% and
p ≥ 0.34). These four three-study groups represent only
7.9%, 9.4%, 12.0% and 13.7% of the entire study popula-
tion, respectively.
Modified L'Abbé plot and unsupervised clustering analysis
A modified L'Abbé plot of creatinine change in controls
versus creatinine change in NAC-treated subjects for all 22
studies is shown in Figure 5A. The no-effect line is plotted
for reference. Most trials grouped together symmetrically
around the no-effect line, with the exception of four very
Jackknife sensitivity analysis Figure 4
Jackknife sensitivity analysis. Studies are ordered from 
top to bottom by their effect on heterogeneity when 
removed one at a time from the set of 22 studies. Removing 
any of the 10 studies at the top of the plot decreases hetero-
geneity, while removing any of the 12 studies at the bottom 
of the plot increases heterogeneity. The four studies that 
individually contributed the most to heterogeneity are shown 
as open circles. Circle size is proportional to the inverse var-
iance.
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Funnel plot of precision versus log RR. Log RR of devel-
oping CIN is plotted versus precision for each of the 22 stud-
ies in this meta-analysis. Four studies later identified as 
contributing most to heterogeneity are noted with open cir-
cles and are seen to produce asymmetry in the plot. The 
summary log RR for all 22 studies is denoted by the open dia-
mond.
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Table 2: Meta-regression of study and patient factors
Characteristic r* p-value
Study-related Publication date (months 
after first)
0.36 0.1
Study size (number of 
patients)
0.14 0.54
Jadad score (1–5) 0.07 0.75
Total NAC dose (mg) -0.26 0.25
Patient-related Age (years) -0.13 0.56
Baseline Creatinine (mg/dl) -0.01 0.96
Diabetes mellitus (%) -0.23 0.31
Female (%) 0.1 0.72
Contrast volume (ml) -0.27 0.24
CIN event rate in control 
group (%)
0.21 0.35
*A negative correlation coefficient implies more benefit as the tested 
independent variable increases.BMC Medicine 2007, 5:32 http://www.biomedcentral.com/1741-7015/5/32
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beneficial, relatively small studies [10,11,14,25]. These
same four studies had caused the appearance of asymme-
try in the funnel plot and were associated with heteroge-
neity by jackknife-k analysis. As suggested by the L'Abbé
plot, a box plot (Figure 5B) of creatinine change clearly
shows that these four studies have relatively large creati-
nine increases in control patients (p = 0.02; open boxes on
the left-hand side) and relatively large creatinine decreases
in NAC-treated patients (p  = 0.07; open boxes on the
right-hand side).
Using a model-based, unsupervised clustering approach
[87], our modified L'Abbé plot defined two different sub-
populations of trials within the overall meta-analysis (Fig-
ure 6A). Dividing the 22 PRCTs based on their assignment
to cluster 1 (18 studies, 89% of patients) [12,13,15-24,26-
31] or cluster 2 (four studies, 11% of patients)
[10,11,14,25], these two sets of trials were found to have
significantly different treatment effects (p < 0.0001) and
both were internally homogeneous (Figure 6B). Group
membership likelihoods were greater than 90% for the 18
studies assigned to cluster 1 and greater than 99% for the
four studies assigned to cluster 2. Cluster 1 studies (2445
patients) showed no benefit from NAC administration to
prevent CIN (RR = 0.87; 95% CI 0.68–1.12, p = 0.28).
Cluster 2 studies (301 patients) indicated a large benefit
from NAC treatment (RR = 0.15; CI 0.07–0.33, p  <
0.0001). The four highly beneficial trials in cluster 2 all
employed oral NAC at low or moderate doses and in this
regard were not different in design from some larger trials
that grouped with cluster 1. Likewise, cluster 2 patients
received iopromide, ioxilan or iopamidol, contrast agents
which did not appear to explain the large apparent benefit
of NAC in these studies. However, cluster 2 studies were
published earlier, are smaller in size and of lower quality
as measured by Jadad scores (Table 3; p = 0.01, three study
characteristics combined). Notably, control subjects expe-
rienced more CIN in cluster 2 compared with cluster 1 tri-
als (31% ± 10% versus 12% ± 6%; p  = 0.03). These
increased episodes of CIN in cluster 2 were not associated
with any consistent pattern of patient-related characteris-
tics that increase risk for CIN (Table3).
Power analysis
A power analysis was performed using the point estimate
of the treatment effect in cluster1 trials (RR = 0.87) to pro-
vide the most conservative estimate of the size of a trial
necessary to show a significant effect. A single PRCT com-
paring NAC treatment with control subjects, in a balanced
design, would need to enroll 32 200 patients in order to
have an 80% chance of showing a significant benefit of
NAC to prevent CIN at the p < 0.05 level. This assumes
that the diagnosis of CIN would be based on similar cut-
off values for a change in creatinine [10-31].
Changes in creatinine across all trials Figure 5
Changes in creatinine across all trials. A: Modified L'Abbé plot of change in creatinine from baseline to study endpoint in 
the control arm (x-axis) versus NAC treatment arm (y-axis) of each study. Studies are weighted by inverse variance (i.e. larger 
symbols represent larger studies with less variability). Open circles denote cluster 2 studies [10, 11, 14, 25]. B: Box plot of 
change in creatinine from baseline to study endpoint in the control arm and NAC treatment arm of each study. Boxes repre-
sent the 25th, 50th and 75th percentiles. Whiskers are 5th and 95th percentiles. Dashed lines show the mean of each group. 
Open squares denote cluster 2 studies.
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Dialysis events after contrast
The occurrence of dialysis was examined in the 22 trials
meeting our inclusion criteria (n = 2746). A total of 13
patients received dialysis post-contrast (control n  = 5,
NAC-treated n = 8; p = 0.42) with no difference in the use
of dialysis in cluster 1 (control n = 4, NAC-treated n = 8; p
= 0.26) and cluster 2 (control n = 1, NAC-treated n = 0; p
= 1.0) between the two treatment arms. NAC treatment
showed no evidence of being protective using the clinical
endpoint of dialysis events (RR = 1.42; CI 0.46–4.39, p =
0.54).
Examination of new studies published after our cut-off 
date
From September 30, 2004 to March 1, 2007, 14 clinical
trials of NAC in CIN were published [58-69]. Nine studies
[58-64,70,71] met our prospective inclusion criteria. Like
our meta-analysis of 22 PRCTs, these nine trials (1151
patients) had significant heterogeneity (I2 = 56.0%; p =
0.03). When the nine studies were added to our meta-
analysis, significant heterogeneity was again observed (I2
= 40.9%; p = 0.01). Our model-based, unsupervised clus-
tering approach showed that eight of these trials [58-
63,70,71] grouped with cluster 1 with a probability of
group membership of more than 94% for each trial. This
updated cluster 1 (26 studies, 3268 patients) had low,
non-significant heterogeneity (I2 = 8.3%; p = 0.34) and
Cluster analysis based on changes in creatinine Figure 6
Cluster analysis based on changes in creatinine. A: Modified L'Abbé plot showing the results of model-based, unsuper-
vised cluster analysis. Unlike Figure 5A, studies are unweighted for easier visualization. Cluster analysis (see the Methods sec-
tion) applied to the 22 studies found two distinct populations of trials. Crosshairs and circles denote the mean ± SD of each 
cluster. B: Aggregate NAC treatment effect and heterogeneity analysis of each cluster. The entire group of 22 studies had 
unacceptable heterogeneity (I2 = 37%; p = 0.04) making the summary point estimate unreliable (not shown). Cluster 1 (n = 18; 
2445 patients) is homogeneous and shows no benefit (RR = 0.87; 95% CI 0.68–1.12, p = 0.28). Cluster 2 (N = 4; 301 patients) 
is also homogeneous and indicates that NAC is very beneficial (RR = 0.15; 95% CI 0.07–0.33, p < 0.0001).
A. B.
Favors NAC
0.1 1 10
Cluster 2
Cluster 1
N
Δ Creatinine Control (mg/dL)
-0.6 -0.4 -0.2 0.0 0.2 0.4 0.6
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
Cluster 2
Cluster 1
0 0.55
0 0.99
I2
p-value for
heterogeneity
4
18
Favors Control
Δ
Creatinine
NAC
(mg/dL)
Table 3: Comparison of cluster 1 and cluster 2 studies (mean ± SD)
Characteristic Cluster 1 Cluster 2 p-value†
Study-related Publication date (months after first) 38 ± 8 22 ± 17 0.05
Study size (number of patients) 136 ± 106 75 ± 35 0.23
Jadad score (1–5) 2.9 ± 1.5 2.0 ± 1.4 0.24
All three factors combined 34 ± 13 50 ± 9 0.01
Patient-related Age (years) 68 ± 4 70 ± 3 0.24
Baseline creatinine (mg/dl) 1.6 ± 0.4 2.2 ± 0.6 0.09
Diabetes mellitus (%) 43 ± 13 45 ± 13 0.93
Female (%) 31 ± 14 22 ± 9 0.31
Contrast volume (ml) 158 ± 61 122 ± 46 0.11
† Wilcoxon rank sum testBMC Medicine 2007, 5:32 http://www.biomedcentral.com/1741-7015/5/32
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showed no benefit of NAC for preventing CIN (RR = 0.90;
95% CI 0.72–1.12, p = 0.35). Cluster 1 and 2 treatment
effects remained significantly different (p < 0.0001).
One study of both high- and low-dose intravenous NAC
in patients with acute myocardial infarctions [64] did not
group strongly with either cluster (probabilities of group
membership: low-dose arm, 39% for cluster 1 and 61%
for cluster 2; high-dose arm, 49% for cluster 1 and 51%
for cluster 2). Based on these results, this study [64] was
found to be an outlier (p < 0.05; Dixon test) [98] com-
pared with other trials assigned to either cluster 1 or 2.
Hemodialysis risk model
We tested for a correlation between CIN and the clinically
more rigorous outcome of dialysis. The correlation was
weighted by the inverse variance of each study. Of the 22
trials in our meta-analysis and the nine more recent stud-
ies, hemodialysis events occurred in a total of nine trials
[12,15,16,18-21,58,64]. Figure 7 shows that the RR of
CIN, as defined in each trial, is positively correlated with
the RR of requiring dialysis post-contrast (r = 0.66; p =
0.038). However, the regression equation is shifted
upwards from the line of identity. For the RR of dialysis to
be on the side of benefit (RR < 1.0), the RR of CIN would
need to be substantially below one (RR < 0.67 for CIN).
In fact, observing a RR of CIN this low in any future clini-
cal trial is unlikely based on our cluster analysis, because
it lies outside the 95% CI for cluster 1. A trial enrolling 32
200 patients, as described in the power analysis, would
also have a moderate likelihood of showing a harmful
effect of NAC on the need for post-contrast dialysis (RR =
1.29).
Discussion
The limited ability of meta-analysis to address unex-
plained heterogeneity has been explored in a well-known
data set that has been subjected to a large number of pre-
vious investigations. CIN is a common and important
complication of diagnostic imaging that has a substantial
impact on morbidity and mortality [91-94]. While hydra-
tion is clearly beneficial in preventing CIN [99,100], NAC
has been investigated in many trials and subsequent meta-
analyses with no consistent answer as to its efficacy. This
meta-analysis of 22 studies, like previous meta-analyses
[72-83], has demonstrated significant heterogeneity. The
inconsistency across studies was systematically explored.
Funnel plots [4-6] and a reiterative sensitivity analysis
[97] both identified subsets of studies that appeared to be
most strongly associated with this problem. However, a
standard meta-regression approach [1,2,84] failed to
identify a single study or patient-related characteristic that
correlated with or fully explained variability in the NAC
treatment effect. Ultimately, a modified L'Abbé plot [86]
that substituted change in creatinine, a directly measured
continuous endpoint, for CIN event rates, an all-or-noth-
ing outcome that was variably defined across trials, indi-
cated the possibility of distinct trial subpopulations
within the overall results. Borrowing from our experience
in functional genomics research, unsupervised, model-
based clustering [87] was applied to demonstrate that the
data set represented two homogeneous, significantly dif-
ferent trial populations. This novel approach allowed us
to directly compare trials that populated each of the two
dissimilar clusters and provided a reliable aggregate point
estimate for performing a formal power analysis.
NAC prophylaxis for the prevention of CIN was first intro-
duced in 2000 [10] and although definitive proof of effi-
cacy has been elusive, the use of NAC prophylaxis has
become widespread. NAC trials have mainly been con-
ducted in stable patient populations with at least one risk
factor for the development of CIN [10-68]. Small doses of
NAC given orally have been the most frequently investi-
gated regimen despite evidence that the drug is poorly
absorbed and undergoes significant first-past metabolism
[101]. Although vigorous hydration has been demon-
strated as an effective preventive strategy [99], NAC trials
have typically been conducted using no more than main-
tenance infusions (1 ml/kg/h) of half-normal or normal
saline [10-31]. Whether the small, non-significant benefit
of NAC in cluster 1 of our meta-analysis would persist if
hydration were individually optimized is questionable.
Importantly, a large PRCT of unselected patients undergo-
ing elective coronary angiography found that normal
Hemodialysis risk model Figure 7
Hemodialysis risk model. Relative risk of developing CIN 
is plotted versus RR of needing hemodialysis, based on 
hemodialysis data available from nine studies. Axes are in log-
arithmic scale. The RR of CIN would have to be less than 
0.67 in order for the RR of hemodialysis not to be on the 
side of harm (RR < 1).
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compared with half-normal saline reduced the incidence
of CIN almost threefold [100]. Merten et al. [102]
reported a negligible incidence of CIN in subjects treated
with a sodium bicarbonate infusion at 3 ml/kg/h before
contrast followed by 1 ml/kg/h after contrast. These stud-
ies suggest that fluid administration regimens have a large
impact on CIN risk. It is worth noting that all four highly
beneficial studies in cluster 2 of our meta-analysis
[10,11,14,25] employed protocols specifying half-normal
saline infusions at 1 ml/kg/h.
Changes in serum creatinine levels have invariably been
used to diagnose CIN in trials of NAC. However, serum
creatinine is a poor surrogate marker for glomerular filtra-
tion rate (GFR) because creatinine is influenced by diet,
endogenous production, renal filtration, secretion and
reabsorption [103,104]. Contrast agents themselves may
decrease creatinine secretion and thereby raise serum cre-
atinine levels, independently of changes in GFR [105].
Conversely, NAC in the absence of contrast has been
shown to decrease serum creatinine levels in normal vol-
unteers [106] and patients [66]. Hoffmann et al. [106]
detected significant NAC-induced decreases in serum cre-
atinine that were not associated with similar changes in
cystatin C. As cystatin C is not secreted by renal tubule
cells it may be a more accurate indicator of GFR
[107,108]. Interestingly, in our meta-analysis, three out of
the four cluster 2 studies [10,11,14] and one cluster 1
study [17], shown by sensitivity analysis to make a rela-
tively large contribution to heterogeneity, all reported
substantial NAC-induced decreases in serum creatinine.
This response to NAC may be a drug effect independent of
changes in GFR.
The four highly beneficial studies (cluster 2) represent
only 11% of patients in our meta-analysis. These trials
were significantly different from cluster 1 studies in that
they had early publication dates, were small in size and of
low quality. Furthermore, cluster 2 studies uniformly
employed an inferior hydration regimen that may have
exaggerated any effects of NAC treatment. Cluster 2 stud-
ies were characterized by relatively large serum creatinine
increases in control patients and similarly large creatinine
decreases in NAC-treated patients.
A power analysis of cluster 1 studies indicated that 32 200
patients would be needed in a single PRCT to have an
80% chance of detecting benefit using definitions of CIN
based on serum creatinine. Importantly, dialysis use was
not decreased by NAC treatment across the 2746 patients
in our meta-analysis. The large PRCT just proposed would
have a moderate likelihood of demonstrating harm as
measured by the more rigorous clinical endpoint of dialy-
sis. Based on this investigation, low-dose oral NAC has
not been shown to prevent CIN and should not be rou-
tinely recommended.
Eight of the nine new trials published since we closed our
meta-analysis [58-63,70,71] were found to group with
cluster 1 and support our overall findings. One of the tri-
als was an outlier and not only reported significant reduc-
tions in CIN rates, but also decreases in dialysis use and
mortality [64]. In this study, very ill patients with acute
myocardial infarctions were treated with intravenous
NAC boluses during angioplasty [64]. As noted by the
authors, these single-center results require confirmation.
As survival improved in their trial, Marenzi et al. specu-
lated about possible benefits of NAC beyond the simple
prevention of CIN [64]. Alternatively, the relatively high
mortality in control subjects might also be explained by
hidden imbalances created during randomization. In con-
trast to this highly beneficial trial, other studies in high-
risk patients undergoing coronary bypass [109] or abdom-
inal aortic surgery [110] did not find that intravenous
NAC reduced the incidence of postoperative renal dys-
function or mortality.
Conclusion
Our meta-analysis does not support the use of NAC for
reducing rates of acute kidney injury due to intravascular
iodinated contrast. In several overly influential trials
showing large beneficial effects, NAC decreased serum cre-
atinine levels, suggesting possible drug effects independ-
ent of true changes in GFR. Dialysis use across all studies
occurred infrequently, but did not indicate that NAC was
efficacious. Future clinical trials of therapies to prevent
CIN should incorporate primary endpoints other than
change in creatinine.
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